Astrana Health, Inc. Form 8-K Summary
Business Context and Reporting Period
This Current Report on Form 8-K was filed by Astrana Health, Inc. (ASTH) on February 26, 2025. The filing primarily details the entry into a material definitive agreement to restructure the Company's debt facilities and announces the date for the 2025 Annual Meeting of Stockholders.
Key Financial Metrics and Debt Structure
The Company entered into a Second Amended and Restated Credit Agreement establishing a total credit facility of $1.295 billion, structured as follows:
- Revolving Credit Facility: $300 million (five-year term), including a $100 million letter of credit sub-facility and a $25 million swingline loan sub-facility.
- Term Loan A: $250 million (five-year term).
- Delayed Draw Term Loan: $745 million (five-year term).
Interest Rates and Fees:
- Interest: Term SOFR plus 1.25% to 2.50% or Base Rate plus 0.25% to 1.50%, determined quarterly based on leverage ratio.
- Commitment Fee: 0.175% to 0.35% on unused revolving commitments.
- Ticking Fee: 0.175% to 0.35% on unused delayed draw term loan commitments.
Financial Covenants (Effective Q2 2025):
- Maximum Total Net Leverage Ratio: 5.00:1.00 (through March 31, 2027), reducing to 4.50:1.00 thereafter.
- Minimum Interest Coverage Ratio: 2.50:1.00.
Use of Proceeds: Refinancing existing indebtedness, paying transaction costs, working capital, general corporate purposes, future permitted acquisitions, and financing the acquisition of assets from Prospect Medical Holdings, Inc.
Material Changes and Events
The primary material change is the replacement of the previous credit agreement (dated June 16, 2021) with the new $1.295 billion facility. The Company and its subsidiary, Astrana Health Management, Inc., granted a security interest in all assets to the lenders. Additionally, the Board of Directors set June 11, 2025, as the date for the 2025 Annual Meeting of Stockholders, which will be conducted virtually.
Outlook, Risks, and Contingencies
The filing does not provide specific revenue guidance or management commentary on future operating performance. However, the agreement imposes significant negative covenants restricting dividends, distributions, fundamental changes, and additional indebtedness. The Company must maintain specific leverage and coverage ratios commencing with the fiscal quarter ending June 30, 2025. Failure to comply with covenants or occurrence of an event of default could allow lenders to terminate commitments, demand immediate repayment, and exercise rights over pledged securities.
Key Facts for Investor Verification
- Verify the specific terms of the asset and equity purchase agreement with Prospect Medical Holdings, Inc., dated November 8, 2024, which the delayed draw term loan is intended to finance.
- Confirm the Company's current leverage ratio to assess compliance with the new 5.00:1.00 covenant threshold effective June 30, 2025.
- Review the full text of the Second Amended and Restated Credit Agreement (Exhibit 10.1) for detailed definitions of "Total Net Leverage Ratio" and "Interest Coverage Ratio."
- Monitor the status of the refinancing of existing indebtedness to ensure no prepayment penalties or cross-defaults were triggered during the transition.